CoChat

2-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication

Open access

The DOI matches its Crossref record; 68 of the 70 references it cites were found in a registry or an index.

Abstract

The persistence of the AIDS epidemic, and the life-long treatment required, indicate the constant need of novel HIV-1 inhibitors. In this scenario the HIV-1 Reverse Transcriptase (RT)-associated ribonuclease H (RNase H) function is a promising drug target. Here we report a series of compounds, developed on the 2-amino-6-(trifluoromethyl)nicotinic acid scaffold, studied as promising RNase H dual inhibitors. Among the 44 tested compounds, 34 inhibited HIV-1 RT-associated RNase H function in the low micromolar range, and seven of them showed also to inhibit viral replication in cell-based assays with a selectivity index up to 10. The most promising compound, 21, inhibited RNase H function with an IC50 of 14 µM and HIV-1 replication in cell-based assays with a selectivity index greater than 10. Mode of action studies revealed that compound 21 is an allosteric dual-site compound inhibiting both HIV-1 RT functions, blocking the polymerase function also in presence of mutations carried by circulating variants resistant to non-nucleoside inhibitors, and the RNase H function interacting with conserved regions within the RNase H domain. Proving compound 21 as a promising lead for the design of new allosteric RNase H inhibitors active against viral replication with not significant cytotoxic effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules25061338

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Structure of dual-site dual inhibitors. In red, the functionalized spacer; in black, the aromatic side portions. Summary of the 2-(arylamino)-6-(trifluoromethyl)nicotinic acid derivatives, in blue squares; the aromatic side portions, within red square.
Figure 1 Structure of dual-site dual inhibitors. In red, the functionalized spacer; in black, the aromatic side portions. Summary of the 2-(arylamino)-6-(trifluoromethyl)nicotinic acid derivatives, in blue squares; the aromatic side portions, within red square.CC BY · PubMed Central
Scheme 1 Synthetic routes to compounds 6, 11–52. (i) MeCN, r.t.; (ii) MeCN reflux; (iii) 20% aq NaOH, 100 °C; (iv) 50% aq H2SO4, 100 °C; (v) ArOH, EDCI, OHBt, MeCN, r.t.; vi) RNH2, EDCI, OHBt, MeCN, r.t.
Scheme 1 Synthetic routes to compounds 6, 11–52. (i) MeCN, r.t.; (ii) MeCN reflux; (iii) 20% aq NaOH, 100 °C; (iv) 50% aq H2SO4, 100 °C; (v) ArOH, EDCI, OHBt, MeCN, r.t.; vi) RNH2, EDCI, OHBt, MeCN, r.t.CC BY · PubMed Central
Scheme 2 Synthetic route to compound 9. (i) MeCN, r.t.; (ii) MeCN, reflux.
Scheme 2 Synthetic route to compound 9. (i) MeCN, r.t.; (ii) MeCN, reflux.CC BY · PubMed Central
Figure 2 Effect of MgCl2 on the absorbance spectra of 2-(arylamino)-6-(trifluoromethyl)nicotinic acid derivatives. Mg2+ chelation UV-Vis spectrum was measured with 100 µM of compound alone (unbroken line) or in the presence of 6 mM MgCl2 (dotted line). The active site RNase H inhibitor RDS1759 was used as reference.
Figure 2 Effect of MgCl2 on the absorbance spectra of 2-(arylamino)-6-(trifluoromethyl)nicotinic acid derivatives. Mg2+ chelation UV-Vis spectrum was measured with 100 µM of compound alone (unbroken line) or in the presence of 6 mM MgCl2 (dotted line). The active site RNase H inhibitor RDS1759 was used as reference.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

Metadata

Authors
Corona, A., Onnis, V., Del Vecchio, C., Esposito, F., Cheng, Y.-C., & Tramontano, E.
Affiliations
  • University of Cagliari (IT)
  • Department of Molecular Medicine, University of Padova, 35121 Padova, Italy
  • Yale University (US)
  • University of Padua (IT)
Corresponding author
Tramontano, Enzo
Venue
Molecules
Publisher
MDPI AG
Published
2020-03-15
Volume
25
Issue
6
Pages
1338
ISSN
1420-3049 (ISSN-L)
OpenAlex
W3012081745
Cited by
19
References
70
Citations by year
2026: 3 · 2025: 1 · 2024: 6 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 2
FWCI
0.29
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, cc-by)
Funders
Regione Autonoma della Sardegna (F76C18000800002)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
HIV-1 reverse transcriptase, RNase H, dual inhibitors, allosteric inhibitors, HIV-1 replication inhibition, antiviral drug design, non-nucleoside reverse transcriptase inhibitors, drug selectivity index, viral replication
MeSH terms
Allosteric Regulation, Humans, Virus Replication, HIV-1, Ribonuclease H, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Cell Line, Tumor, HIV Reverse Transcriptase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.